Expression of the p53 tumour suppressor gene as a prognostic marker in platinum-treated patients with ovarian cancer

European Journal of Cancer

Volumn 34, Issue 6, 1998, Pages 845-850

  Marx, D ^a   Meden, H ^a   Ziemek, T ^a   Lenthe, T ^a   Kuhn, W ^a   Schauer, A ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Chemotherapy; Ovarian cancer; P53; Prognosis; Tumour suppressor gene

Indexed keywords

PLATINUM; PROTEIN P53;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; FEMALE; FOLLOW-UP STUDIES; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032077390     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)10169-1     Document Type: Article

References (29)

1. Meden H, Marx D, Roegglen T, Schauer A, Kuhn W. Over-expression of the oncogene c-erbB-2 (HER2/neu) and response to chemotherapy in patients with ovarian cancer. Int J Gynecol Pathol 1998, 17,61-65.
2. van-der-Zee AG, Hollema H, Bruijn HW de, et al. Cell biological markers of drug resistance in ovarian carcinoma. Gynecol Oncol 1995, 58, 165-178.
3. Dive G, Hickman JA. Drug-target interactions: only the first step in the commitment to a programmed cell death. Br J Cancer 1991,64, 192-196.
4. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991, 351, 453-456.
5. Lane D. p53, guardian of the genome. Nature 1992, 358, 15-16.
6. Kastan MB, Camman CE, Leonard CJ. P53, cell cycle control and apoptosis: implications for cancer. Cancer Metastasis 1995, 14,3-15.
7. Perego P, Giarola M, Rhigetti SC, et al. Association between cisplatin resistance and mutations of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 1996, 56, 556-562.
8. Eliopoulus AG, Kerr DJ, Herod J, et al. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl2. Oncogene 1995, 11, 1217-1228.
9. Lowe S, Ruley HE, Jacks T, Housman DE. P53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993, 74, 957-967.
10. Nabeya Y, Loganzo F, Maslak P, et al. The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. Int J Cancer 1995, 64, 37-46.
11. van-der-Zee AG, Hollema H, Suurmeijer AJ, et al. Value of pglycoprotein, glutathione S-transferase pi, c-erbB-2 and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 1995, 13, 70-78.
12. Renninson J, Baker BW, McGown AT, et al. Immunohistochemical detection of mutant p53 protein in epithelial ovarian cancer using polyclonal antibody CMI: correlation with histopathology and clinical features. Br J Cancer 1994, 69, 609-612.
13. Righetti SC, Della Torre G, Pilotti S, et al. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 1996, 56, 689-693.
14. Buttitta F, Marchetti A, Gadducci A, et al. p53 Alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br J Cancer 1997, 75, 230-235.
15. Fan S, Smith ML, Rivet DJ, et al. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 1995, 55, 1649-1654.
16. Stal O, Stenmark-Askmalm M, Wingren S, et al. P53 expression and the result of adjuvant therapy of breast cancer. Acta Oncol 1995, 34, 767-770.
17. Aas T, Borresen AL, Geisller S, et al. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996, 2, 811-814.
18. Gannon JV, Greaves RV, Iggo R, Lane DP. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 1990, 9, 1595.
19. Serov SF, Scully RE, Sobin LH. Histological typing of ovarian cancer tumors. In World Health Organization. International Histological Classification of Tumors. Geneva, World Health Organization, 1973.
20. Marx D, Meden H, Brune T, et al. Mib-1 evaluated proliferative activity in ovarian cancer with respect to prognostic significance. Anticancer Res 1997, 17, 775-780.
21. Meden H, Marx D, Rath W, et al. Overexpression of the oncogene c-erb B2 in primary ovarian cancer: evaluation of the prognostic value in a Cox proportional hazards multiple regression. Int J Gynecol Pathol 1994, 13, 45-53.
22. Kaplan E, Meier P. Non parametric estimation from incomplete observation. J Am Stat Assoc 1958, 53, 457-481.
23. Levesque MA, Katsaros D, Yu H, et al. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 1994,75, 1327-1338.
24. Henriksen R, Strang P, Wilander E, Bäckstrom T, Tribukait B, Oberg K. p53 expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry. Gyn Oncology 1994, 53, 301-306.
25. Hartmann LC, Podratz KG, Keeney GL, et al. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol 1994, 12,64-69.
26. Klemi PJ, Pylkkänen L, Kiilholma P, Kurvinen K, Joensuu H. p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 1995, 76, 1201-1208.
27. Brown R, Clugston C, Burns P, et al. Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer 1993, 55, 678-684.
28. Kastan MB, Onyekwere O, Sidransky B, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991, 51, 6304-6311.
29. Lambkin HA, Mothersill CM, Kelehan P. Variation in immunohistochemical detection of p53 protein overexpression in cervical carcinomas with different antibodies and methods of detection. J Pathol 1994, 172, 13-18.